2. Protein Tyrosine Kinase/RTK Stem Cell/Wnt MAPK/ERK Pathway
  3. FGFR ERK
  4. GP369

GP369 is a humanized FGFR2-IIIb-specific antibody. GP369 significantly inhibits the proliferation of tumor cells. GP369 can significantly inhibit phosphorylation of FGFR2 and downstream signaling pathways. GP369 can be used for research on cancer such as gastric cancer and breast cancer.

For research use only. We do not sell to patients.

GP369 Chemical Structure

GP369 Chemical Structure

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

GP369 Related Antibodies

Top Publications Citing Use of Products

View All ERK Isoform Specific Products:

View All Isoforms
ERK ERK1 ERK2 ERK5 ERK8

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

GP369 is a humanized FGFR2-IIIb-specific antibody. GP369 significantly inhibits the proliferation of tumor cells. GP369 can significantly inhibit phosphorylation of FGFR2 and downstream signaling pathways. GP369 can be used for research on cancer such as gastric cancer and breast cancer[1].

IC50 & Target[1]

FGFR2

 

In Vitro

GP369 (0.001-1000 nM, 2-5 days) can significantly inhibit the proliferation of various cells, including FDCP-1, SUM52PE and MCF7 cells[1].
GP369 (0.001-100 nM, 2 days) inhibits FGFR2 IIIb driven proliferation and has no effect on FGFR2 IIIc in FDCP-1 (IC50 = 1.4 nM) cells[1].
GP369 (30 μg/mL, 3 days) inhibits proliferation induced by FGF7 (25 ng/mL) in MCF7 cells[1].
GP369 (10 μg/mL, 1-48 h) suppresses FGFR2 and ERK1/2 phosphorylation and downstream signaling in Ba/F3 and SNU-16 cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

GP369 Related Antibodies

Cell Proliferation Assay[1]

Cell Line: FDCP-1 cells
Concentration: 0.001-100 nM
Incubation Time: 2 days
Result: Significantly inhibited FGFR2 IIIb driven proliferation, including FGFR2 IIIb WT, FGFR2 IIIb N550K and FGFR2 IIIb S252W.

Western Blot Analysis[1]

Cell Line: SNU-16 cells
Concentration: 10 μg/mL
Incubation Time: 2, 6, 24 and 48 h
Result: Reduced the level of FGFR2 protein.

Western Blot Analysis[1]

Cell Line: Ba/F3 cells and SNU-16 cells
Concentration: 5 μg/mL
Incubation Time: Incubated for1 h and then combinated with FGF7 for 15 min
Result: Significantly inhibited FGF7 induced phosphorylation and downstream protein levels, including p-FGFR and p-ERK1/2.
In Vivo

GP369 (2-20 mg/kg; i.p.; twice weekly; for 43 days) significantly inhibits tumor growth and reduces FGFR2 phosphorylation and protein levels in C.B-17 severe combined immunodeficient (SCID) mice bearing SNU-16 xenografts[1].
GP369 (20 mg/kg, i.p.; twice weekly; for 27 days) realizes tumor arrest and significantly reduces FGFR2 phosphorylation and protein levels in NCr nude mice bearing MFM-223 xenografts[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female C.B-17 SCID mice bearing 5×106 SNU-16 cells (10 weeks)[1]
Dosage: 2, 5, 10 and 20 mg/kg
Administration: Intraperitoneal injection (i.p.); twice weekly for 43 days
Result: Significantly inhibited changes in tumor volume.
Significantly reduced the level of FGFR2 and p-FGFR.
Animal Model: 1×107 MFM-223 cells injected female NCr nude mice (5 weeks)[1]
Dosage: 20 mg/kg
Administration: Intraperitoneal injection (i.p.); twice weekly for 27 days
Result: Significantly inhibited changes in tumor volume.
Significantly reduced the level of FGFR2 and p-FGFR.
Gene ID

2263  [NCBI]

Accession
Target

FGFR2/CD332
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
SMILES

N/A
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

GP369 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

GP369GP 369GP-369FGFRERKFibroblast growth factor receptorExtracellular signal regulated kinasesFGFR2ERK1/2gastric cancerbreast cancerInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
GP369
Cat. No.:
HY-P991583
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.